Letters
HPV quadrivalent vaccine
Authors’ reply to Fiala
BMJ 2012; 344 doi: https://doi.org/10.1136/bmj.e3198 (Published 08 May 2012) Cite this as: BMJ 2012;344:e3198
- Elmar A Joura, associate professor1,
- Heather L Sings, director, global scientific and medical publications2,
- Richard M Haupt, executive director, clinical research2
- 1Department of Gynaecology and Obstetrics, Medical University of Vienna, Comprehensive Cancer Centre, A-1090 Vienna, Austria
- 2Merck Sharp and Dohme, Whitehouse Station, NJ, USA
- elmar.joura{at}meduniwien.ac.at
The findings in table 3 are not unexpected.1 2 As Brown and colleagues reported,3 and we stated in our paper,2 the FUTURE I and II clinical trials showed that vaccination reduced the incidence of cervical intraepithelial neoplasia grade 3 or worse associated with 10 non-vaccine human papillomavirus (HPV) types by 32.5% (95% CI 6.0% to 51.9%). The analyses in table …
Log in
Log in using your username and password
Log in through your institution
Subscribe from £138 *
Subscribe and get access to all BMJ articles, and much more.
* For online subscription
Access this article for 1 day for:
£23 / $37 / €30 (inc. VAT)
You can download a PDF version for your personal record.